Pfizer Inc announced that the company has signed a letter of intent for the development and commercialization with Taisho Pharmaceutical Co

Pfizer Inc and  Taisho Pharmaceutical Co have signed a letter of intent for the development and commercialization rights of Taisho's schizophrenia drug candidate outside Japan. Pfizer said the agreement would grant Pfizer the exclusive development and commercialization rights for TS-032, a new schizophrenia drug candidate discovered by Taisho and in the pre-clinical stage.

Taisho Pharmaceutical Co., Ltd. and Pfizer Inc. have concluded a letter of intent with regard to TS-032, a new schizophrenia drug candidate discovered by Taisho and currently in the pre-clinical stage.